Skip to content

Paradoxical Depressive Response to Intranasal Esketamine in Treatment-Resistant Depression: A Case Series.

Jose A Ontiveros-Sánchez de la Barquera, Luis Alberto De La Garza García, Silvia Viridiana Esquivel García, Guillermo Sánchez Torres, Grecia Alejandra Perez Jalomo

The American journal of case reports December 28, 2024 DOI: 10.12659/AJCR.945475 via PubMed

Summary

AI-generated from the abstract

Two patients with treatment-resistant depression initially improved with intranasal esketamine but then experienced rapid worsening of depressive symptoms and suicidal ideation. After stopping esketamine, both patients clinically improved and their suicidal thoughts diminished. The cause of this paradoxical reaction is unclear, but the report highlights that such adverse responses can occur even when treatment initially appears effective. Clinicians should be aware of this potential complication.

Study at a glance

Characteristics Case report Peer reviewed
Sample size 2
Population Patients with treatment-resistant depression
Intervention intranasal esketamine
Topics Depression Esketamine
Keywords Adverse effects Antidepressants Psychiatric medication
Citations 2
Key finding Two patients with treatment-resistant depression showed paradoxical worsening of depressive symptoms and suicidal ideation after initial improvement with intranasal esketamine, which resolved upon discontinuation.

Abstract

BACKGROUND Esketamine is the only pharmacological agent with glutamatergic neuromodulator properties approved by the US Food and Drug Administration and European Medicines Agency to enhance the effects of serotonin selective or serotonin and norepinephrine reuptake inhibitors. Treatment-resistant depression (TRD) is a challenging and prevalent condition in the psychiatric field, in which patients often experience persistent and severe depressive symptoms, as well as a higher risk of suicidal thoughts and attempts. Esketamine has demonstrated its safety and effectiveness as a pharmacological therapy for TRD. Our report aims to present 2 cases of depressive symptom deterioration and suicide ideation in patients treated with esketamine. CASE REPORT We present 2 cases of TRD that initially responded well to intranasal esketamine but later deteriorated rapidly, with a worsening of depressive symptoms and suicidal ideation. Upon discontinuing esketamine, both patients clinically improved and showed a reduction in suicide ideation. The evaluation of affective symptoms' response to esketamine and evolution was assessed using the Montgomery-Asberg Scale and Clinical Global Impression Severity and Improvement scales. CONCLUSIONS The underlying cause for the paradoxical antidepressant reaction is not entirely clear, but we observed this phenomenon in 2 patients with TRD who were treated with esketamine. Identifications of paradoxical reactions could be difficult in TRD, with highly resistant responses to treatment and suicidal ideation. However, it is relevant to know the prevalence of this phenomenon and for clinicians to be aware of the complications of esketamine treatment.

Explore topics

Comments

No comments yet.

Log in to comment